mab-fto-check

To check monoclonal antibody freedom to operate risk, you need a workflow that performs sequence alignment, keyword search, and claim decomposition. This process filters patents by jurisdiction and competitor to identify potential infringement risks for your antibody candidate.

Yes, FTO risk assessment for bispecific antibodies and ADCs is supported. The workflow handles target, indication, and market-level patent clearance, including specific reviews for Fc engineering, linker, and payload chemical-structure matching.

Analyzing patent claims for design-around guidance requires claim decomposition and comparison against your antibody sequence. The workflow ranks infringement risks and produces structured findings to help navigate around existing monoclonal antibody patent protections.

The best way to search sequence alignments for antibody FTO is using a controlled workflow that combines sequence matching with chemical-structure matching and competitor mapping. This ensures comprehensive patent family merging and legal-status review across target jurisdictions.

Yes, the FTO workflow generates an HTML report with linked patent citations and legal-status handling. This report-ready output includes structured findings for risk ranking, claim comparison, and design-around recommendations for your monoclonal antibody program.

Filtering antibody patents by jurisdiction and legal status is achieved through family merging and jurisdiction filtering within the FTO workflow. This process organizes patent search results to isolate active protections and map competitor portfolios in your target markets.